Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.66 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.60 |
| ▸ | QPCT | Q16769 | 6/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9059896 | 0.89 | NAMPT (0.52) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL11580425 | 0.85 | QPCT (0.63) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL15551905 | 0.81 | NAMPT (0.74) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL5265936 | 0.80 | NAMPT (0.66) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL24819856 | 0.80 | NAMPT (1.00) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL21774243 | 0.79 | QPCT (0.63) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL24819770 | 0.79 | QPCT (0.56) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL30050799 | 0.77 | QPCT (0.75) | NAMPTP2RY14QPCTEPHX1RAB9A | |
| SCHEMBL15551102 | 0.77 | NAMPT (0.72) | NAMPTP2RY14CYP3A4P2RY6QPCT | |
| SCHEMBL24028037 | 0.76 | QPCT (0.56) | NAMPTP2RY14CYP3A4P2RY6QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0158888-B1 | DISAZO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-01-24 | — | — | EP | claimed |
| EP-0158889-B1 | AMINO AZO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-30 | — | — | EP | claimed |
| EP-0158888-A2 | Disazo compounds, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | claimed |
| EP-0158889-A2 | Amino azo compounds, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | claimed |
| JP-8295810-A | — | — | None | — | — | JP | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| EP-4149928-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2023-03-22 | — | — | EP | disclosed |
| CN-115697974-A | Imidazole 3-oxide derivative based ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021229571-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2021-11-18 | — | — | WO | disclosed |
| CN-111763174-A | Method for reducing distillation residues of 5-acetoacetylaminobenzimidazolone mother liquor | 山东汇海医药化工有限公司 | 2020-10-13 | — | — | CN | disclosed |
| JP-H08295810-A | PIGMENT AND COLORING COMPOSITION FOR COLOR FILTER | TOYO INK MFG CO LTD | 1996-11-12 | — | — | JP | disclosed |
| EP-0158888-B1 | DISAZO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4686287-A | ORANGE PIGMENTS FOR INKS, PAINTS, PLASTICS, RUBBERS, PRINTING | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-08-11 | — | — | US | disclosed |
| EP-0158888-A2 | Disazo compounds, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | NAMPT 968/4885P2RY14 4747/4885CYP3A4 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.